SynCore Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 2.58%

SynCore Biotechnology Co Ltd (4192) has an Asset Resilience Ratio of 2.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is SynCore Biotechnology Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

NT$7.04 Million
≈ $221.67K USD Cash + Short-term Investments

Total Assets

NT$272.85 Million
≈ $8.60 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how SynCore Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 4192 asset base.

Liquid Assets Composition Over Time

This chart breaks down SynCore Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 4192 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$7.04 Million 2.58%
Total Liquid Assets NT$7.04 Million 2.58%

Asset Resilience Insights

  • Limited Liquidity: SynCore Biotechnology Co Ltd maintains only 2.58% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

SynCore Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare SynCore Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for SynCore Biotechnology Co Ltd (2015–2024)

The table below shows the annual Asset Resilience Ratio data for SynCore Biotechnology Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.19% NT$6.96 Million
≈ $219.15K
NT$317.80 Million
≈ $10.01 Million
+0.43pp
2023-12-31 1.76% NT$6.66 Million
≈ $209.83K
NT$378.36 Million
≈ $11.92 Million
+0.23pp
2022-12-31 1.53% NT$6.66 Million
≈ $209.83K
NT$436.65 Million
≈ $13.76 Million
+0.72pp
2021-12-31 0.81% NT$6.66 Million
≈ $209.83K
NT$824.44 Million
≈ $25.97 Million
+0.08pp
2020-12-31 0.73% NT$6.66 Million
≈ $209.83K
NT$913.99 Million
≈ $28.80 Million
-0.14pp
2019-12-31 0.87% NT$6.66 Million
≈ $209.83K
NT$763.88 Million
≈ $24.07 Million
+0.04pp
2018-12-31 0.83% NT$6.66 Million
≈ $209.83K
NT$804.80 Million
≈ $25.36 Million
+0.04pp
2017-12-31 0.79% NT$6.66 Million
≈ $209.83K
NT$845.89 Million
≈ $26.65 Million
+0.19pp
2016-12-31 0.60% NT$6.66 Million
≈ $209.83K
NT$1.11 Billion
≈ $35.12 Million
-0.05pp
2015-12-31 0.65% NT$6.63 Million
≈ $208.82K
NT$1.03 Billion
≈ $32.36 Million
--
pp = percentage points

About SynCore Biotechnology Co Ltd

TWO:4192 Taiwan Biotechnology
Market Cap
$20.11 Million
NT$638.24 Million TWD
Market Cap Rank
#25186 Global
#1551 in Taiwan
Share Price
NT$18.15
Change (1 day)
-6.68%
52-Week Range
NT$18.15 - NT$28.30
All Time High
NT$537.12
About

SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more